Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38010 | 0.95 | CNR2 (0.52) | CNR2PARP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL31202632 | 0.95 | CNR2 (0.52) | CNR2PARP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14995793 | 0.88 | GRIN2D (0.46) | CNR2PARP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL77785 | 0.82 | CNR2 (0.49) | CNR2PARP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL25668035 | 0.81 | CNR2 (0.48) | CNR2PARP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL15491939 | 0.79 | CNR2 (0.47) | CNR2PARP1 | |
| SCHEMBL14408313 | 0.78 | PARP1 (0.54) | CNR2PARP1F10PIM1KLKB1 | |
| SCHEMBL5172659 | 0.78 | PARP1 (0.57) | CNR2PARP1ALDH1A1CCNCCDK8 | |
| SCHEMBL14910345 | 0.77 | CNR2 (0.53) | CNR2PARP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL31333194 | 0.76 | PARP1 (0.47) | CNR2PARP1MEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | CNR2 4059/4885PARP1 3860/4885GRIN2D 4475/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | CNR2 4059/4885PARP1 3860/4885GRIN2D 4475/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | CNR2 4059/4885PARP1 3860/4885GRIN2D 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.